The largest blog for reading the latest medical research on all disease, the prevention and its treatment . Pulled from variety of sources

Tuesday, December 20, 2016

Acadia says Alzheimer's disease psychosis drug clears study according to : "news-medical"

This content may collect you by Lucy William

We will quote to you the news of the best health sites Like : "news-medical" and the most famous medical experts :


daily : 2016-12-20 & on time : 13:45


follow all the new news about Disease

as declared in





Landmark clinical trial to test third investigational drug for Alzheimer's disease


Landmark clinical trial to test third investigational drug for Alzheimer's disease
image uploaded by "news-medical" site
An international team led by Washington University School of Medicine in St. Louis has selected a third investigational drug to be tested in a worldwide clinical trial - already underway - aimed at finding treatments to prevent Alzheimer's disease.The third drug is being developed by Janssen Research & Development, LLC, in New Jersey.It is designed to lower production of amyloid beta, a protein that clumps together into plaques and damages neurons in the brain, leading to memory loss, cognitive problems and confusion.The drug is designed to block the enzyme beta secretase -- which produces amyloid beta -- with a goal of reducing the amount of amyloid beta available to clump and cause neurodegeneration.
about the details read more from here


Acadia says Alzheimer's disease psychosis drug clears study


Acadia says Alzheimer's disease psychosis drug clears study
image uploaded by "dailymail" site
Acadia says Alzheimer's disease psychosis drug clears studyDec 20 (Reuters) - Acadia Pharmaceuticals Inc said on Tuesday its drug to treat psychosis in patients suffering from Alzheimer's disease met its main goal in a mid-stage study.The company said the drug, pimavanserin, showed a statistically significant reduction in psychosis with a 3.76 point improvement at week 6, compared with 1.93 for placebo.Acadia said a total of 181 patients were enrolled in the study in the UK and randomized on a one-to-one basis to receive either 34 mg of pimavanserin or placebo once everyday.The drug has been approved by the US Food and addiction Administration to treat hallucinations and delusions associated with Parkinson's disease psychosis, the company said.
about the details read more from here


New biomarker predicts Alzheimer's disease and link to diabetes


New biomarker predicts Alzheimer's disease and link to diabetes
image uploaded by "medicalxpress" site
Diagram of the brain of a person with Alzheimer's Disease.Credit: Wikipedia/public domain.An enzyme found in the fluid around the brain and spine is giving researchers a snapshot of what happens inside the minds of Alzheimer's patients and how that relates to cognitive decline.Iowa State University researchers say higher levels of the enzyme, autotaxin, significantly predict memory impairment and Type 2 diabetes.
about the details read more from here


To follow all the new news about Disease !!! All you need to know about all kinds of diseases

No comments:

Post a Comment